← Back to Clinical Trials
Recruiting NCT06331130

NCT06331130 Mesenteric Infiltration in Ovarian Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06331130
Status Recruiting
Phase
Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Condition Ovary Cancer
Study Type OBSERVATIONAL
Enrollment 510 participants
Start Date 2024-03-01
Primary Completion 2025-06-30

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Computed Tomography

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 510 participants in total. It began in 2024-03-01 with a primary completion date of 2025-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To evaluate if CT features at diagnosis in patients with HGSOC can be used to build an Artificial Intelligence model capable of discerning the pathological involvement of the mesentery, assessing the potential impediments for an optimal debulking surgery and predicting the development of resistance to platinum based chemotherapeutic agents.

Eligibility Criteria

Inclusion Criteria: 1. Women with confirmed HGSOC wiht mesenteric involvment 2. Age \> 18 years 3. FIGO STAGE IIIB-IV 4. Primary diagnosis 5. Signed informed consent Exclusion Criteria: 1. Non-serous high grade epithelial ovarian cancer (serous low grade, mucinous, clear cell carcinoma, endometrioid or non-epithelial ovarian cancer) 2. Early stage disease (I and II stage) 3. CT scan not available 4. Non-primary diagnosis or patient subjected to neoadjuvant chemotherapy

Contact & Investigator

Central Contact

Camilla Panico, Dr

✉ camilla.panico@policlinicogemelli.it

📞 +390630155701

Principal Investigator

Camilla Panico, Dr

PRINCIPAL INVESTIGATOR

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Frequently Asked Questions

Who can join the NCT06331130 clinical trial?

This trial is open to female participants only, aged 18 Years or older, studying Ovary Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06331130 currently recruiting?

Yes, NCT06331130 is actively recruiting participants. Contact the research team at camilla.panico@policlinicogemelli.it for enrollment information.

Where is the NCT06331130 trial being conducted?

This trial is being conducted at Roma, Italy.

Who is sponsoring the NCT06331130 clinical trial?

NCT06331130 is sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The principal investigator is Camilla Panico, Dr at Fondazione Policlinico Universitario Agostino Gemelli IRCCS. The trial plans to enroll 510 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology